The GRPEL2 Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1975 human lung adenocarcinoma line. This product provides a heterogeneous pool of cells harboring targeted disruptions of the GRPEL2 gene, enabling robust loss-of-function analyses without the confounding effects of clonal selection. The polyclonal design captures the inherent variability of CRISPR/Cas9 editing, delivering a biologically representative model for mitochondrial research in cancer.
The host NCI-H1975 cell line is a well-established human non-small cell lung adenocarcinoma model harboring activating mutations in EGFR: L858R in exon 21 and T790M in exon 20. These mutations drive constitutive oncogenic signaling and confer resistance to first-generation EGFR tyrosine kinase inhibitors, establishing a clinically relevant background for studying mitochondrial adaptations in aggressive, drug-resistant NSCLC.
GRPEL2 encodes a mitochondrial nucleotide exchange factor that specifically regulates the Hsp70 chaperone mortalin (HSPA9), a central component of the TIM23 translocase. By catalyzing ADP-to-ATP exchange on mortalin, GRPEL2 promotes the release and folding of newly imported precursor proteins, a step critical for mitochondrial protein import, iron-sulfur cluster biogenesis, and maintenance of mitochondrial membrane potential. Its expression is transcriptionally controlled by factors such as NRF1, HSF1, and PGC-1??, thereby integrating metabolic and proteostatic signals. Functionally, GRPEL2 operates within a molecular network comprising HSPA9, TIMM44, the TIM23 complex, and the PAM complex, with downstream effects on HSP60 and iron-sulfur protein assembly. Thus, GRPEL2 sits at a nexus of mitochondrial quality control, linking protein handling to ATP synthesis and redox metabolism.
In the NCI-H1975 context, GRPEL2 knockout disrupts mitochondrial protein homeostasis, likely triggering the mitochondrial unfolded protein response and impairing oxidative phosphorylation. This perturbation exposes vulnerabilities in the mitochondrial chaperone system that may be particularly relevant in EGFR-driven lung cancer cells, which rely on robust mitochondrial function for survival and drug resistance. The model thus provides a powerful tool to dissect the interplay between oncogenic signaling and mitochondrial proteostasis.
Researchers can apply this model for metabolic flux analysis using Seahorse, iron-sulfur cluster integrity measurements via aconitase activity assays, and in vitro mitochondrial protein import studies. High-throughput drug screening targeting mitochondrial chaperones, coupled with Annexin V apoptosis assays, identifies novel therapeutic sensitivities. Immunofluorescence and co-immunoprecipitation enable exploration of GRPEL2 interactions with HSPA9 and TIMM44. Standard molecular techniques such as western blotting and RT-qPCR facilitate monitoring of UPRmt markers and regulators like NRF1 and HSF1. For further information, contact Ascent Research.
